These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32317463)

  • 1. Commentary: Systemic immune-inflammatory indices and their association with ocular disorders-Do we have economical and reliable biomarkers?
    Madanagopalan VG
    Indian J Ophthalmol; 2020 May; 68(5):859-860. PubMed ID: 32317463
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary: Our understanding of central serous chorioretinopathy-coming a full circle?
    Mohan A; Soman M; Nair RU
    Indian J Ophthalmol; 2020 May; 68(5):858-859. PubMed ID: 32317462
    [No Abstract]   [Full Text] [Related]  

  • 3. Comments on: Monocyte to high-density lipoprotein ratio in central serous chorioretinopathy: A biomarker of inflammation or epiphenomenon.
    Jain M; Gerges F
    Indian J Ophthalmol; 2021 Feb; 69(2):471. PubMed ID: 33463624
    [No Abstract]   [Full Text] [Related]  

  • 4. Monocyte to high-density lipoprotein and neutrophil-to-lymphocyte ratios in patients with acute central serous chorioretinopathy.
    Sirakaya E; Duru Z; Kuçuk B; Duru N
    Indian J Ophthalmol; 2020 May; 68(5):854-858. PubMed ID: 32317461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to comments on: Monocyte to high-density lipoprotein and neutrophil-to-lymphocyte ratios in patients with acute central serous chorioretinopathy.
    Sirakaya E; Duru Z; Kuçuk B; Duru N
    Indian J Ophthalmol; 2021 Feb; 69(2):472. PubMed ID: 33463625
    [No Abstract]   [Full Text] [Related]  

  • 6. Central serous chorioretinopathy and systemic corticosteroids in rheumatic diseases: report of three cases.
    Valls Pascual E; Martínez-Costa L; Santander F
    BMC Musculoskelet Disord; 2015 Dec; 16():378. PubMed ID: 26638151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary: Hyperreflective dots - An imaging biomarker of inflammation?
    Agarwal A
    Indian J Ophthalmol; 2019 Nov; 67(11):1855-1856. PubMed ID: 31638048
    [No Abstract]   [Full Text] [Related]  

  • 8. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
    Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A
    BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary: Management of central serous chorioretinopathy: Looking beyond the eye.
    Agarwal A; Gupta A
    Indian J Ophthalmol; 2018 Dec; 66(12):1714-1715. PubMed ID: 30451171
    [No Abstract]   [Full Text] [Related]  

  • 10. Central serous chorioretinopathy, corticosteroids, and uveitis.
    Khairallah M; Kahloun R; Tugal-Tutkun I
    Ocul Immunol Inflamm; 2012 Apr; 20(2):76-85. PubMed ID: 22409559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central serous chorioretinopathy and glucocorticoids: an update on evidence for association.
    Nicholson BP; Atchison E; Idris AA; Bakri SJ
    Surv Ophthalmol; 2018; 63(1):1-8. PubMed ID: 28673727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Central serous chorioretinopathy following the use of phosphodiesterase 5 inhibitors].
    Smal C; Lepièce G; Bonnet S
    Rev Med Liege; 2017 Nov; 72(11):475-477. PubMed ID: 29171944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: Multicolor imaging: A new imaging tool in central serous chorioretinopathy.
    Venkatesh R; Pereira A; Sangai S; Singh V; Sridharan A
    Indian J Ophthalmol; 2020 May; 68(5):866-867. PubMed ID: 32317465
    [No Abstract]   [Full Text] [Related]  

  • 14. Commentary: Low incidence of pachydrusen in central serous chorioretinopathy in an Indian cohort.
    Sheth JU
    Indian J Ophthalmol; 2020 Jan; 68(1):124-125. PubMed ID: 31856488
    [No Abstract]   [Full Text] [Related]  

  • 15. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report.
    Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S
    J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Irvine Gass syndrome and central serous chorioretinopathy, pure coincidence or non fortuitous association? Report of three cases].
    Boulanger G; Weber M
    J Fr Ophtalmol; 2009 Oct; 32(8):566-71. PubMed ID: 19656588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serous central chorioretinopathy and tadalafil: a case report].
    Nadeau S; Nguyen F; Guigou S
    J Fr Ophtalmol; 2012 Feb; 35(2):121.e1-5. PubMed ID: 21680058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
    Yang D; Eliott D
    Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central serous chorioretinopathy during pregnancy complicated by systemic hypertension - a case report.
    Gawecki M; Groszewska E
    Klin Oczna; 2016 Sep; 117(4):256-259. PubMed ID: 29727113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central Serous Chorioretinopathy: A Complication Associated with Behçet’s Disease Treatment.
    Doğanay N; Balıkoğlu Yılmaz M; Orduyılmaz B; Aydın E; Saatçi AO
    Turk J Ophthalmol; 2019 Feb; 49(1):40-43. PubMed ID: 30829024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.